Construction method of ace2 gene modified golden hamster model and application thereof
By constructing a digital twin model and using a multi-index scoring system to select donor hamsters, the problem of experimental failure caused by blind selection in existing technologies has been solved, and the success rate and experimental efficiency of gene editing in the Ace2 gene-modified golden hamster model have been improved.
Patent Information
- Application Number
- CN202611339007.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies cannot predict which individual will be the best donor or recipient before constructing an Ace2 gene-modified golden hamster model, leading to significant blindness in the experiment and wasting a large amount of precious breeding stock.
A digital pre-evaluation model was constructed by collecting multi-dimensional data, a multi-index comprehensive scoring system was used to select donor hamsters, and the gene modification effect was predicted by a simulation system to generate a list of recommended best donors. Physical modeling was established by combining genotype identification and expression verification.
It significantly improved the success rate of gene editing, reduced the number of experimental animals used, and lowered experimental costs and blind spots.
Smart Images

Figure CN123063459A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of constructing genetically engineered animal models, and in particular to a method for constructing an Ace2 gene-modified golden hamster model and its application. Background Technology
[0002] The golden hamster is a small rodent belonging to the genus *Cricetidae* in the family Cricetidae. It is also known as the Syrian hamster, golden bear, or Syrian hamster. Wild-type golden hamsters naturally possess a high binding affinity between their endogenous hACE2 and the SARS-CoV / SARS-CoV-2 spike protein RBD, allowing them to be infected with the novel coronavirus without the need for exogenous hACE2 transfer. This makes them a classic small animal model for COVID-19.
[0003] The ACE2 gene-modified golden hamster is a genetic engineering model obtained by using gene editing techniques such as CRISPR-Cas9 to knock out, humanize, and modify the endogenous Ace2 in hamsters through point mutation. It is used to overcome the limitations of wild-type hamsters and to accurately study ACE2 function and virus-host interaction.
[0004] However, the genetic backgrounds and physiological states of different golden hamster individuals vary, and their embryonic development capabilities, tolerance to micromanipulation, and responsiveness to gene editing tools are all different. Current technology cannot predict which individual will be the best donor or recipient before constructing a model, resulting in a large degree of blindness in the experiment and the waste of a large amount of precious breeding stock.
[0005] Therefore, it is necessary to provide a method for constructing an Ace2 gene-modified golden hamster model and its application to solve the above-mentioned technical problems. Summary of the Invention
[0006] This invention provides a method for constructing an Ace2 gene-modified golden hamster model and its application, which solves the problem that existing technologies cannot predict which individual will be the best donor or recipient before constructing the model, resulting in a large degree of blindness in the experiment and the consumption of a large amount of precious breeding resources.
[0007] To solve the above-mentioned technical problems, the present invention provides a method for constructing an Ace2 gene-modified golden hamster model, comprising the following steps: S1: Select multiple golden hamsters for multidimensional data collection, construct a digital pre-evaluation model, and select donor hamsters through a multi-index comprehensive scoring system; S1-1: Select golden hamsters for multidimensional data collection; S1-2: Construct an individualized "digital twin" model based on the multidimensional data collected in S1-1; S1-3: Based on the research objectives, clarify the specific goals of this model construction; S1-4: Substitute "digital twins" of different candidate hamsters into the simulation system, and simulate and predict according to the preset gene modification targets; S1-5: Based on the simulation results, the system comprehensively scores and ranks the candidate hamsters and outputs a recommended list of "best donor hamsters"; S2: Constructing a human ACE2 gene expression cassette; S3: Insert the human ACE2 gene expression cassette into the recombinase-mediated cassette exchange donor plasmid to prepare the donor plasmid and helper plasmid; S4: Select the donor hamsters selected in step S1 to collect fertilized eggs, mix the donor plasmid and the helper plasmid and then microinject them into the male pronucleus of the fertilized eggs. S5: After the injected fertilized eggs are cultured in vitro to the two-cell stage, they are then transferred to a pseudopregnancy recipient. S6: Screening for positive individuals by conducting genotyping; S7: Establish physical modeling data by performing expression verification and strain testing.
[0008] Preferably, the multidimensional data mentioned in step S1-1 includes basic physiological data, blood biochemical indicators, hormone levels, genetic background data, and historical reproductive data.
[0009] Preferably, the basic physiological data includes the golden hamster's breed, age, sex, weight, estrous cycle stage, and birth history; the blood biochemical indicators include blood lipid levels, blood glucose, and liver function indicators; the hormone levels include follicle-stimulating hormone, luteinizing hormone, progesterone, and estradiol; the genetic background data includes ACE2 gene polymorphism site information, Irs2 gene status, and ApoE gene status; and the historical reproductive data includes the number of eggs retrieved during previous superovulation, fertilization rate, two-cell rate, and live birth rate.
[0010] Preferably, the specific target parameters in steps S1-3 include the editing type, the target region, and the editing precision requirement. The editing type is explicitly defined as knockout, conditional knockout, point mutation, and gene knock-in. The target region is a specific target exon of the ACE2 gene. The editing precision requirement is a clearly defined tolerance threshold for off-target rate.
[0011] Preferably, the prediction directions of the simulation system in steps S1-4 include predicting the theoretical response success rate, predicting the potential off-target effect risk, and predicting the expected phenotypic changes.
[0012] Preferably, in steps S1-4, the simulation system generates a list of candidate donors sorted by comprehensive score, along with a detailed interpretation of each predicted score. In the recommended list, the individual with the highest comprehensive score is the best donor.
[0013] Preferably, the comprehensive score in step S1-5 is calculated as follows: Comprehensive score = α × (theoretical cutting efficiency score) + β × (1 - normalized off-target risk score) + γ × (phenotypic prediction confidence score).
[0014] Preferably, the physical modeling data is fed back to the simulation system, and the system compares the simulation results of the candidate hamster in steps S1-5 with the actual experimental physical modeling data and calculates the deviation value.
[0015] Preferably, based on the deviation value analysis results, the system adjusts the parameters and retrains the prediction model.
[0016] An application of a method for constructing an Ace2 gene-modified golden hamster model, wherein the Ace2 gene-modified golden hamster model is used in at least one of the following (1)-(5): (1) To study the related functions and mechanisms of action of the ACE2 gene; (2) To study the infection mechanism of SARS-CoV-2 virus; (3) Evaluation of novel pathogenic strains of SARS-CoV-2; (4) Screening for drugs to treat SARS-CoV-2 virus infection; (5) Develop vaccines to prevent SARS-CoV-2 virus infection.
[0017] Compared with related technologies, the method for constructing an Ace2 gene-modified golden hamster model and its application provided by this invention have the following beneficial effects: This invention provides a method for constructing an Ace2 gene-modified golden hamster model and its application. By constructing a digital twin of the donor and inputting it into a simulation system, the system simulates and predicts based on the preset gene modification target. The candidate donor is quantitatively optimized through digital pre-evaluation, avoiding experimental failures caused by blind selection. Thus, pre-screening is performed through virtual simulation, reducing the number of experimental animals actually used, which can significantly improve the success rate of gene editing and reduce blind selection and experimental costs. Attached Figure Description
[0018] Figure 1 A schematic diagram of the structure of the first embodiment of the method for constructing an Ace2 gene-modified golden hamster model and its application provided by the present invention; Figure 2 for Figure 1 The diagram shows the structure of step S1. Figure 3 This is a schematic diagram of the second embodiment of the method for constructing an Ace2 gene-modified golden hamster model provided by the present invention and its application. Detailed Implementation
[0019] The present invention will be further described below with reference to the accompanying drawings and embodiments. Example
[0020] Please refer to the following: Figure 1 and Figure 2 ,in, Figure 1 A schematic diagram of the structure of the first embodiment of the method for constructing an Ace2 gene-modified golden hamster model and its application provided by the present invention; Figure 2 for Figure 1 The diagram shows the structure of step S1.
[0021] A method for constructing an Ace2 gene-modified golden hamster model includes the following steps: S1: Select multiple golden hamsters for multidimensional data collection, construct a digital pre-evaluation model, and select donor hamsters through a multi-index comprehensive scoring system; S1-1: Select golden hamsters for multidimensional data collection; S1-2: Construct an individualized "digital twin" model based on the multidimensional data collected in S1-1; S1-3: Based on the research objectives, clarify the specific goals of this model construction; S1-4: Substitute "digital twins" of different candidate hamsters into the simulation system, and simulate and predict according to the preset gene modification targets; S1-5: Based on the simulation results, the system comprehensively scores and ranks the candidate hamsters and outputs a recommended list of "best donor hamsters"; S2: Constructing a human ACE2 gene expression cassette; S3: Insert the human ACE2 gene expression cassette into the recombinase-mediated cassette exchange donor plasmid to prepare the donor plasmid and helper plasmid; S4: Select the donor hamsters selected in step S1 to collect fertilized eggs, mix the donor plasmid and the helper plasmid and then microinject them into the male pronucleus of the fertilized eggs. S5: After the injected fertilized eggs are cultured in vitro to the two-cell stage, they are then transferred to a pseudopregnancy recipient. S6: Screening for positive individuals by conducting genotyping; S7: Establish physical modeling data by performing expression verification and strain testing. The multidimensional data mentioned in step S1-1 includes basic physiological data, blood biochemical indicators, hormone levels, genetic background data, and historical reproductive data.
[0022] The basic physiological data includes the golden hamster's breed, age, sex, weight, estrous cycle stage, and birth history. The blood biochemical indicators include blood lipid levels, blood glucose, and liver function indicators. The hormone levels include follicle-stimulating hormone, luteinizing hormone, progesterone, and estradiol. The genetic background data includes ACE2 gene polymorphism information, Irs2 gene status, and ApoE gene status. The historical reproductive data includes the number of eggs retrieved during previous superovulation, fertilization rate, two-cell rate, and live birth rate.
[0023] The specific target parameters in steps S1-3 include the editing type, target region, and editing precision requirements. The editing type is explicitly defined as knockout, conditional knockout, point mutation, and gene knock-in. The target region is a specific target exon of the ACE2 gene. The editing precision requirements are a clearly defined tolerance threshold for off-target rate.
[0024] The prediction directions of the simulation system in steps S1-4 include predicting the theoretical response success rate, predicting the potential off-target effect risk, and predicting the expected phenotypic changes.
[0025] Predicted theoretical response success rate (cutting efficiency): Deep learning-based algorithms (such as DeepHF) are used to predict the cleavage probability of sgRNA designed for the ACE2 gene of an individual. DeepHF uses a recurrent neural network (RNN) framework to generate probabilistic cleavage efficiency scores for different Cas9 variants (such as wild type and high-fidelity type).
[0026] Simulated output: The system outputs a "theoretical cleavage efficiency score" (probability value) for each sgRNA-target combination. The higher the score, the higher the expected success rate of the individual's response to this editing protocol.
[0027] Predicting potential off-target effects: Quantitative analysis was performed using an industry-recognized specificity scoring algorithm. MIT score: Based on location-specific mismatch tolerance weights, it considers the number of mismatches and the average distance between mismatches to predict the probability of off-target cutting.
[0028] CFD score: It is an optimization based on MIT score, taking into account the different influence weights of different nucleotide substitution types (such as A→G vs A→T) at specific positions, and is therefore generally considered to be superior to MIT score.
[0029] Simulation output: The system outputs MIT score and CFD score for each potential off-target site to comprehensively assess the risk level.
[0030] Predicted phenotypic changes: Preliminary inferences are made based on the high similarity between the golden Syrian hamster and humans. Hamsters are more similar to humans than mice in terms of metabolism and immunity. Their ACE2 receptor expression and binding characteristics make them highly sensitive to pathogens such as SARS-CoV-2, and they can reproduce the pathological features of human diseases after infection. The system utilizes this known biological background knowledge, combined with specific editing targets (such as conditional knockout of ACE2 in the liver), to predict the expected direction of metabolic or immune function changes.
[0031] Simulated output: A "phenotypic change prediction report" describing the expected changes in physiological or pathological characteristics under this editing scheme.
[0032] In steps S1-4, the simulation system generates a list of candidate donors sorted by comprehensive score, along with a detailed interpretation of each predicted score. The individual with the highest comprehensive score in the recommended list is the best donor, which is used by the experimenters as a basis for decision-making in subsequent wet experiments.
[0033] The comprehensive score in step S1-5 is calculated as follows: Comprehensive score = α × (theoretical cutting efficiency score) + β × (1 - normalized off-target risk score) + γ × (phenotypic prediction credibility score).
[0034] α, β, and γ are adjustable weighting coefficients that can be dynamically adjusted according to specific research objectives (whether to prioritize success rate or safety).
[0035] Compared with related technologies, the method for constructing an Ace2 gene-modified golden hamster model and its application provided by this invention have the following beneficial effects: This invention provides a method for constructing an Ace2 gene-modified golden hamster model and its application. By constructing a digital twin of the donor and inputting it into a simulation system, the system simulates and predicts based on the preset gene modification target. The candidate donor is quantitatively optimized through digital pre-evaluation, avoiding experimental failures caused by blind selection. Thus, pre-screening is performed through virtual simulation, reducing the number of experimental animals actually used, which can significantly improve the success rate of gene editing and reduce blind selection and experimental costs. Example
[0036] Please refer to the following: Figure 3 Based on the first embodiment of this application, which provides a method for constructing an Ace2 gene-modified golden hamster model and its application, the second embodiment of this application proposes another method for constructing an Ace2 gene-modified golden hamster model and its application. The second embodiment is merely a preferred embodiment of the first embodiment, and its implementation will not affect the individual implementation of the first embodiment.
[0037] Specifically, the second embodiment of this application provides a method for constructing an Ace2 gene-modified golden hamster model and its application, which differs in that the physical modeling data is fed back to the simulation system, and the system compares the simulation results of the candidate hamster in steps S1-5 with the real experimental physical modeling data and calculates the deviation value.
[0038] For example, if the predicted cutting efficiency is 85% and the actual positive rate is 70%, then record that the prediction has an overestimation bias of 15%.
[0039] If the predicted off-target risk is low, but multiple off-target sites are actually detected, then the prediction is marked as an underestimation of risk.
[0040] Based on the deviation value analysis results, the system adjusts the parameters and retrains the prediction model.
[0041] Iteration can be achieved in the following ways: Knowledge updates embedded in biological mechanisms: When new real data reveals the efficiency pattern of a certain sgRNA in a hamster, this pattern can be used as a biological constraint to embed into the model structure (similar to the idea of OptiPrime embedding biochemical step knowledge into the model), rather than just doing parameter tuning.
[0042] Data-driven model fine-tuning: Using newly accumulated hamster experimental data (multi-source data + actual results) as the training set, the original deep learning prediction model (such as DeepHF) is fine-tuned to make its prediction of the hamster ACE2 gene more specific.
[0043] Adaptive adjustment of weight coefficients: Based on the accumulated iterative data, the weight coefficients (α, β, γ) of the comprehensive scoring model in step five are automatically optimized to make the scoring logic more consistent with the actual experimental situation.
[0044] Through the above iterations, the valuable data from each round of experiments are transformed into the model's "experience," which continuously improves the accuracy of the digital model's predictions for subsequent candidate hamsters, ultimately forming a closed-loop system of "prediction-screening-experimental verification-data feedback-model evolution-more accurate prediction."
[0045] An application of a method for constructing an Ace2 gene-modified golden hamster model, wherein the Ace2 gene-modified golden hamster model is used in at least one of the following (1)-(5): (1) To study the related functions and mechanisms of action of the ACE2 gene; (2) To study the infection mechanism of SARS-CoV-2 virus; (3) Evaluation of novel pathogenic strains of SARS-CoV-2; (4) Screening for drugs to treat SARS-CoV-2 virus infection; (5) Develop vaccines to prevent SARS-CoV-2 virus infection.
[0046] Compared with related technologies, the method for constructing an Ace2 gene-modified golden hamster model and its application provided by this invention have the following beneficial effects: This invention provides a method for constructing an Ace2 gene-modified golden hamster model and its application. By continuously updating and iterating the data in the simulation system according to the actual experimental structure, the accuracy of the digital model in predicting subsequent candidate hamsters is continuously improved.
[0047] The above description is merely an embodiment of the present invention and does not limit the patent scope of the present invention. Any equivalent structural or procedural transformations made based on the content of the present invention specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of the present invention.
Claims
1. A method for constructing an Ace2 gene-modified golden hamster model, characterized in that, Includes the following steps: S1: Select multiple golden hamsters for multidimensional data collection, construct a digital pre-evaluation model, and select donor hamsters through a multi-index comprehensive scoring system; S1-1: Select golden hamsters for multidimensional data collection; S1-2: Construct an individualized "digital twin" model based on the multidimensional data collected in S1-1; S1-3: Based on the research objectives, clarify the specific goals of this model construction; S1-4: Input "digital twins" of different candidate hamsters into the simulation system, and simulate and predict according to the preset gene modification targets; S1-5: Based on the simulation results, the system comprehensively scores and ranks the candidate hamsters and outputs a recommended list of "best donor hamsters"; S2: Constructing a human ACE2 gene expression cassette; S3: Insert the human ACE2 gene expression cassette into the recombinase-mediated cassette exchange donor plasmid to prepare the donor plasmid and helper plasmid; S4: Select the donor hamsters selected in step S1 to collect fertilized eggs, mix the donor plasmid and the helper plasmid and then microinject them into the male pronucleus of the fertilized eggs. S5: After the injected fertilized eggs are cultured in vitro to the two-cell stage, they are then transferred to a pseudopregnancy recipient. S6: Screening for positive individuals by conducting genotyping; S7: Establish physical modeling data by performing expression verification and strain testing.
2. The method for constructing an Ace2 gene-modified golden hamster model according to claim 1, characterized in that, The multidimensional data mentioned in step S1-1 includes basic physiological data, blood biochemical indicators, hormone levels, genetic background data, and historical reproductive data.
3. The method for constructing an Ace2 gene-modified golden hamster model according to claim 2, characterized in that, The basic physiological data includes the golden hamster's breed, age, sex, weight, estrous cycle stage, and birth history. The blood biochemical indicators include blood lipid levels, blood glucose, and liver function indicators. The hormone levels include follicle-stimulating hormone, luteinizing hormone, progesterone, and estradiol. The genetic background data includes ACE2 gene polymorphism information, Irs2 gene status, and ApoE gene status. The historical reproductive data includes the number of eggs retrieved during previous superovulation, fertilization rate, two-cell rate, and live birth rate.
4. The method for constructing an Ace2 gene-modified golden hamster model according to claim 1, characterized in that, The specific target parameters in steps S1-3 include the editing type, target region, and editing precision requirements. The editing type is explicitly defined as knockout, conditional knockout, point mutation, and gene knock-in. The target region is a specific target exon of the ACE2 gene. The editing precision requirements are a clearly defined tolerance threshold for off-target rate.
5. The method for constructing an Ace2 gene-modified golden hamster model according to claim 1, characterized in that, The prediction directions of the simulation system in steps S1-4 include predicting the theoretical response success rate, predicting the potential off-target effect risk, and predicting the expected phenotypic changes.
6. The method for constructing an Ace2 gene-modified golden hamster model according to claim 5, characterized in that, In steps S1-4, the simulation system generates a list of candidate donors sorted by comprehensive score, along with a detailed interpretation of each predicted score. The individual with the highest comprehensive score in the recommended list is the best donor.
7. The method for constructing an Ace2 gene-modified golden hamster model according to claim 1, characterized in that, The comprehensive score in step S1-5 is calculated as follows: Comprehensive score = α × (theoretical cutting efficiency score) + β × (1 - normalized off-target risk score) + γ × (phenotypic prediction credibility score).
8. The method for constructing an Ace2 gene-modified golden hamster model according to claim 1, characterized in that, The physical modeling data is fed back to the simulation system, which compares the simulation results of the candidate hamster in steps S1-5 with the actual experimental physical modeling data and calculates the deviation value.
9. The method for constructing an Ace2 gene-modified golden hamster model according to claim 8, characterized in that, Based on the deviation value analysis results, the system adjusts the parameters and retrains the prediction model.
10. An application of a method for constructing an Ace2 gene-modified golden hamster model, characterized in that, The Ace2 gene-modified golden hamster model according to any one of claims 1-9 is used in at least one of the following (1)-(5): (1) To study the related functions and mechanisms of action of the ACE2 gene; (2) To study the infection mechanism of SARS-CoV-2 virus; (3) Evaluation of novel pathogenic strains of SARS-CoV-2; (4) Screening for drugs to treat SARS-CoV-2 virus infection; (5) Develop vaccines to prevent SARS-CoV-2 virus infection.
